Terbutaline and an 18-Month Ban: The File of a 17-Year-Old Indian Swimmer

In February 2026, a sample taken from a 17-year-old Indian swimmer returned a positive result for terbutaline. Seven months later, his name was struck from India's squad for the Asian Games in Japan, along with an 18-month suspension. The statement did not name him, citing the fact that he is a minor. But domestic reports were forced to mention a detail that makes the story far messier than a routine doping file: his twin brother still holds his place on the Indian team.

One half of the pair has left the water. The other is still swimming, at the same Games, in the same month. And because the two brothers carry near-identical names, international results databases have for years recorded one brother's times under the other's name, to the point where their junior records cannot be cleanly separated.

For anyone who works with data, that is the worst possible starting point. When the identity field is corrupted, every layer of analysis built on top of it drifts, and nobody knows by how much.

The timeline of a file

The administrative sequence is clear. The swimmer returned a positive test in February. The Swimming Federation of India (SFI) withdrew his name from the Commonwealth Games roster and later from the Asian Games roster. He had qualified to race two events at the meet in Japan. An expedited hearing took place last week, with the federation hoping the case would close early enough for him to line up. The outcome was an 18-month ban.

The substance was terbutaline, a beta-2 agonist commonly prescribed for asthma, emphysema, bronchitis and other lung diseases, per the Mayo Clinic. According to the Times of India, he suffered smoke inhalation and took the medication with a doctor's approval, but did not properly obtain a therapeutic use exemption. He did list the substance on his doping control form.

Those last two details sit at the centre of what follows. Honest declaration and authorised use are two entirely different states, and confusing them is the most common error made by people who read numbers.

Terbutaline: a prescription is not a permit

Terbutaline is not among the asthma medications permitted by inhalation. Within the World Anti-Doping Agency's prohibited list framework, terbutaline belongs to the beta-2 agonist class that is banned at all times; it carries no inhaled exception of the kind granted to salbutamol or formoterol. Authorised use therefore requires a TUE granted before competition. A doctor's prescription establishes a medical need. It does not replace a permit from an anti-doping authority.

Beta-2 agonists are tightly controlled not because they are useless against asthma, but because at high oral or injectable doses they enhance performance. Anti-doping bodies do not classify substances by the user's intent; they classify by threshold and by paperwork. A swimmer inhaling asthma medication because his lungs will not open, and a swimmer ingesting asthma medication to boost ventilation, produce the same molecule in a urine sample.

This is why the TUE process exists. Under the standard procedure used by anti-doping organisations, an exemption request should be filed roughly a month before competition, with a diagnosis, lung function results and a treatment plan, so a medical panel can rule before the substance enters the athlete's body. Filing late, or filing incorrectly, turns a completely real condition into a completely real violation.

For a 17-year-old, most of that procedural weight rests on other people: the team doctor, the federation's administrative staff, the medical panel. Where that infrastructure is thin, the cost of a mistake is passed down to the person least able to defend himself in the chain.

The penalty framework follows the same logic. The baseline is four years. A panel can reduce it to two if it finds the violation was not intentional. Below two years sits a further range of reductions, dependent on how persuasive the athlete's explanation is. Eighteen months sits in the middle of that range. So what does the number 18 measure? It measures the quality of an explanation file more than it measures the degree of cheating. That is the point missed in most commentary I have read on this case.

One professional memory makes me sensitive to that kind of distortion. In 2026, while working mid-level at a sports news outlet in Hai Phong, I rebuilt the last 15 matches of a Brazilian striker my club was about to sign. His xG was 0.42 per game, but he had scored 11 goals. The number looked so good that the board dismissed my regression warning, and the outcome was two goals in 12 V-League matches. An attractive figure can blind an entire meeting room. The same applies here: a medically valid prescription looks a great deal like a procedurally valid permit, and that resemblance is the trap.

Then there is the macro picture. India is the world's most populous country, yet at the 2026 Summer Olympics it won six medals and no golds. Over the same period, India has led the world in anti-doping rule violations for consecutive years. The popular reading turns those two lines into a verdict on sporting ethics. That reading is methodologically hasty. Turning a violation count into a conclusion requires a denominator: total tests per year, athletes in the registered testing pool, the share of out-of-competition samples, the share of positives found through re-analysis of stored samples. A system that tests more densely will find more violations, by the simplest mathematical definition. Numbers do not lie, but the people who read them do.

There is another hypothesis worth testing, and it connects straight to this file: if a large share of violations sit at the administrative layer — missing TUEs, wrong whereabouts filings, missed out-of-competition tests — then what India lacks is not sporting ethics but athlete support infrastructure. I do not have enough data to assert that, and I will not turn a hypothesis into a conclusion just because it sounds compelling. But if it holds, that 18-month ban is the noise of an under-built sports medicine system, not the signal of a conspiracy.

I have taken part in several comparative sports data projects across China and Vietnam, and one pattern repeats often enough to look like a rule: fast-growing sporting nations break at the administrative layer before they break at the performance layer. Medals arrive late, but medical files and testing registries arrive later still, and both lag behind the growth rate. India has announced ambitions to host the 2036 Summer Olympics. If that happens, testing volumes will rise, anti-doping staffing will rise, and detected violations will most likely rise with them. The violation table will then reflect testing capacity before it reflects anything else. A miracle is just a data point that has not been regressed yet.

India's doping history includes cases where the domestic ruling and the international ruling diverged completely, usually before major Olympics and usually ending at the Court of Arbitration for Sport. Every shock has a portrait inside old data, and that portrait is largely an administrative one.

Finally, the twins. The brothers' international results have been conflated for years, according to domestic reporting itself. Consider the analytical consequences. Every model that rates junior potential, every regression on the improvement curve of an Indian swimmer between 15 and 18, may have been trained on the other brother's data. Nobody notices, because the error sits in the name field, not in the arithmetic. I do not believe in luck; I believe in the margin of error — and here, nobody has measured that margin.

The contrarian angle

The story is being framed around one question: is 18 months light or heavy? That frame sends readers the wrong way from the first line. Inside this file sits a detail that appears in no performance dataset: a 17-year-old inhaled enough smoke to need respiratory medication. Nobody is asking where, when, or under what circumstances. Anti-doping systems can measure a concentration in a urine sample; they have no parameter for the quality of a young athlete's training environment.

A fair counterargument deserves stating before I conclude: if the athlete was prescribed the drug by a doctor and declared it transparently, the sanction may look harsh for a minor. That argument has merit, and anti-doping rules do contain specific reduction routes for minors and for cases of no significant fault. But those very routes demand procedural evidence: the TUE application letter, the team medical panel's confirmation, the filing date. Without infrastructure, the athlete pays in competition time — something no ruling can give back.

There is one further blind spot current data cannot resolve. If both brothers train together, share a team doctor and share a filing process, is the procedural failure on one of them an individual error or a systemic one? Until that is answered, every comment on this case is running on an uncleaned dataset.

Signals for the next cycle

The next data cycle will answer three things. Whether the specific reasoning behind the 18-month figure is published. Whether the TUE pathway for asthma medication among young Indian athletes changes after this case. And how many therapeutic use exemptions are filed on time at the Asian Games in Japan. Data only dies when we stop asking questions. A dataset with corrupted names never lived.